Skip to content
    Samsara BioCapital logo

    Samsara BioCapital

    Palo Alto, California, United StatesFounded 2016
    www.samsaracap.comLinkedIn
    Biotech & Life SciencesHealthcare

    Samsara BioCapital is a venture capital firm founded in 2016 and based in Palo Alto, California. The firm partners with scientists and entrepreneurs to translate cutting-edge science into transformative medicines for patients, investing in innovative therapeutics across the biotech and life sciences sectors.

    44% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (9 deals in the last 12 months vs 14 prior). Their most common stage is series-b (41% of deals). Average disclosed round size is $100.7M (across 170 rounds with reported amounts).

    Find people at Samsara BioCapital on Goldilocks AI

    Portfolio

    116

    Fund Size

    $310.1M

    Top Stage

    Series B

    Last 12 Mo

    9

    Team

    SA

    Srini Akkaraju, MD, PhD

    Founder & Managing Partner

    AB

    Abe Bassan

    Partner

    AE

    Alan Eisenberg

    Venture Partner

    BS

    Betsy Santos

    Venture Partner, Chief People Officer

    DS

    Dan Spiegelman

    Venture Partner

    DP

    David Parry, PhD

    Venture Partner

    ED

    Eric Dobmeier, JD

    Venture Partner

    GR

    Guna Rajagopal, PhD

    Venture Partner

    JP

    Jim P. Edwards, PhD

    Venture Partner

    JO

    John Orwin

    Venture Partner

    KG

    Keith Gottesdiener, MD

    Venture Partner

    MM

    Marcos Milla, PhD

    Venture Partner

    Portfolio Breakdown

    Stage Distribution

    Sector Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    187 investments
    CompanyRoundAmountDate
    Coultreon Biopharma logoCoultreon BiopharmaSeries A$125MApr 2026
    Sidewinder logoSidewinderSeries B$137MApr 2026
    Ambrosia Biosciences Inc. logoAmbrosia Biosciences Inc.Series B$100MMar 2026
    Ambrosia Bio logoAmbrosia BioSeries B$100MMar 2026
    PPrimmune TherapeuticsSeries B$23.3MJan 2026
    EpiBiologics logoEpiBiologicsSeries B—Jan 2026
    SSidewinder TherapeuticsSeries B$137MJan 2026
    Sidewinder logoSidewinderSeries B$137MJan 2026
    Memento Medicines logoMemento MedicinesSeries A$93MJan 2026
    CClaris BioSeries B$57MJan 2026
    Artiva Biotherapeutics logoArtiva BiotherapeuticsSeries B$120MJan 2026
    Coultreon Biopharma logoCoultreon BiopharmaSeries A$125MJan 2026
    Coultreon Biopharma logoCoultreon BiopharmaSeries A$125MJan 2026
    Claris logoClarisSeries B$118MJan 2026
    Ambrosia Bio logoAmbrosia BioSeries B$100MJan 2026
    Psithera logoPsitheraSeries A$47.5MDec 2025
    Link Cell Therapies logoLink Cell TherapiesSeries A$60MDec 2025
    Excellergy Inc. logoExcellergy Inc.Series A$70MOct 2025
    SSpyGlass Pharma, IncSeries D—Jun 2025
    Spyglass logoSpyglassSeries D$75MJun 2025
    Alpheus Medical logoAlpheus MedicalSeries B$52MMay 2025
    AAlpheusSeries B$52MMay 2025
    Alpheus Medical logoAlpheus MedicalSeries A$52MMay 2025
    Surrozen logoSurrozenSeries D$175MMar 2025
    Abcuro, Inc. logoAbcuro, Inc.Series C$200MFeb 2025
    Page 1 of 8

    Top Co-Investors

    RA Capital Management38 shared
    OrbiMed30 shared
    Cormorant Asset Management26 shared
    Surveyor Capital22 shared
    Casdin Capital18 shared
    Rock Springs Capital18 shared
    The Column Group18 shared
    Redmile Group17 shared
    HBM Healthcare Investments15 shared
    Nextech Invest Ltd.15 shared
    Frazier Life Sciences15 shared
    General Catalyst14 shared
    Polaris Partners14 shared
    Logos Capital14 shared
    Foresite Capital14 shared
    Alexandria Venture Investments14 shared
    SR One13 shared
    Cowen Healthcare Investments13 shared
    Catalys Pacific13 shared
    Illumina Ventures13 shared

    Last updated: 20 October 2026